Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

 

PI3Ki's in Indolent Lymphoma: Overview of Approved Drugs, Trial Based Data on Toxicity and Efficacy of Upcoming PI3Ki's, and the Pre-Clinical Rationale of PI3Ki's+Targeted

October 18, 2019

0 Comments
Login to view comments. Click here to Login
Lymphoma